Positive Zurampic Phase III data presented at ACR meeting

Efficacy and safety data from two Phase III extension studies of gout drug Zurampic (lesinurad), as well as pooled analyses from the two extension studies and from the three pivotal Phase III Zurampic clinical trials, in four poster presentations at the American College of Rheumatology (ACR) Annual Meeting in Washington DC, says the drug’s US marketer Ironwood Pharmaceuticals (Nasdaq: IRWD).

The first analysis found that patients treated with lesinurad plus allopurinol in the CLEAR 1 and CLEAR 2 trials who continued treatment in the CLEAR extension study maintained target sUA levels over the full two years.

An analysis of pooled data from patients receiving lesinurad plus XOI in the CLEAR 1, CLEAR 2 or CRYSTAL trials who continued treatment in the CLEAR and CRYSTAL extension studies examined the impact of treatment of lesinurad plus XOI on tophi and flares. This found that patients treated with lesinurad plus an XOI for up to two years exhibited continued increases in the rate of complete resolution of tophi and reduction in tophus area, as well as decreased rates of gout flares.